← Ablatotech Vitals
Pathology EvidenceDigest

Current Evidence on the Use of Spatial Transcriptomics in Tumor Microenvironment Analysis

Pathology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 2, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Spatial transcriptomics is an advancing technology that enables high-resolution mapping of gene expression within the tumor microenvironment (TME), providing critical insights into cellular heterogeneity, tumor-stroma interactions, and immune landscape dynamics. Current evidence demonstrates its utility in identifying fibrosis-related genes, co-evolutionary patterns between tumor and microenvironment, and novel biomarkers for malignancies such as hepatocellular carcinoma and Sézary syndrome. While promising for precision oncology and biomarker discovery, challenges remain in data integration, standardization, and clinical translation. Spatial transcriptomics represents a transformative tool for pathology, with potential to refine diagnosis, prognostication, and therapeutic targeting (Strasser et al., 2025; Qiao et al., 2025).

Clinical bottom line

Spatial transcriptomics is an advancing technology that enables high-resolution mapping of gene expression within the tumor microenvironment (TME), providing critical insights into cellular heterogeneity, tumor-stroma interactions, and immune landscape dynamics. Current evidence demonstrates its utility in identifying fibrosis-related genes, co-evolutionary patterns between tumor and microenvironment, and novel biomarkers for malignancies such as hepatocellular carcinoma and Sézary syndrome. While promising for precision oncology and biomarker discovery, challenges remain in data integration, standardization, and clinical translation. Spatial transcriptomics represents a transformative tool for pathology, with potential to refine diagnosis, prognostication, and therapeutic targeting (Strasser et al., 2025; Qiao et al., 2025).

What the evidence shows

Strasser et al. (2025) performed a multi-scale, multi-omics spatial transcriptomic analysis of Barrett’s esophagus progression to adenocarcinoma, revealing coordinated gene expression changes in both epithelium and stroma. This study highlights how spatial context elucidates tumor evolution and microenvironment remodeling.

Qiao et al. (2025) integrated single-cell RNA sequencing with spatial transcriptomics to identify fibrosis-associated genes in hepatocellular carcinoma, uncovering spatially distinct gene expression patterns linked to fibrotic niches that influence tumor progression.

Abdullah et al. (2026) review the application of artificial intelligence for spatial immunometabolic profiling of the TME, emphasizing enhanced resolution in characterizing immune cell states and metabolic pathways, which may inform immunotherapy strategies.

Li et al. (2025) discuss computational frameworks critical for analyzing spatial transcriptomics data, addressing challenges in data dimensionality and integration with other omics, underscoring the need for robust bioinformatics pipelines.

Roggo et al. (2022) evaluated spatial transcriptomics in Sézary syndrome, demonstrating its capability to identify novel biomarkers and spatially resolved immune signatures, supporting its role in rare hematologic malignancies.

Caveats and uncertainty

Spatial transcriptomics technologies vary in resolution, throughput, and gene coverage, affecting comparability across studies.

High computational complexity and need for specialized bioinformatics expertise limit widespread adoption.

Most studies remain exploratory or preclinical, with limited direct evidence linking spatial transcriptomic findings to clinical outcomes.

Standardized protocols and validation in larger, diverse cohorts are lacking.

Cost and tissue processing requirements may constrain routine clinical implementation.

Integration with existing pathology workflows and regulatory frameworks is ongoing.

How this may change practice

Pathologists may increasingly incorporate spatial transcriptomics to complement histopathology, enabling molecularly informed diagnoses.

Identification of spatially defined biomarkers could refine prognostic stratification and guide personalized therapies.

Spatial mapping of immune and stromal components may improve patient selection for immunotherapies.

Integration with AI-driven analytics promises enhanced interpretation and discovery of therapeutic targets.

Collaborative efforts between pathology, bioinformatics, and oncology will be essential to translate spatial transcriptomics into clinical decision-making.


References

  1. Strasser MK, et al. Concerted changes in Epithelium and Stroma: a multi-scale, multi-omics analysis of progression from Barrett's Esophagus to adenocarcinoma. Dev Cell. 2025; DOI:10.1016/j.devcel.2025.06.034
  2. Qiao W, et al. Integrating single-cell RNA sequencing with spatial transcriptomics reveal the fibrosis-related genes in hepatocellular carcinoma. Front Immunol. 2025; DOI:10.3389/fimmu.2025.1659404
  3. Abdullah I, et al. Artificial Intelligence for Spatial Immunometabolic Analysis of the Tumor Microenvironment: Current Evidence and Future Directions. Curr Issues Mol Biol. 2026; DOI:10.3390/cimb48050476
  4. Li J, et al. Computational Frameworks for Spatial Transcriptomics in Tumor Microenvironment. Comput Mol Biol. 2025; DOI:10.5376/cmb.2025.15.0018
  5. Roggo A, et al. Spatial Transcriptomics of Tumor Microenvironment in Sézary Syndrome - evaluation of a novel method for biomarker discovery. 2022; DOI:10.26226/m.636554144b875b0013a4aa39

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team